WUHAN: Chinese experts have revealed that the phase one and two clinical trials of the world’s first inactivated coronavirus vaccine produced antibodies in participants.
As per details, the vaccine is developed by the Wuhan Institute of Biological Products under the China National Biotec Group (CNBG) affiliated to the China National Pharmaceutical Group (Sinopharm).
The results of the clinical trial showed that the vaccination is safe and has no serious reaction, according to researchers.
They stated that after adopting different procedures and doses of vaccination, all 1,120 participants in the vaccine group produced high titers of antibodies.
All 1,120 volunteers in phase Ⅰ/Ⅱ clinical trials have successfully made #antibodies against the #COVID19 after accepting two doses of the #COVID19 vaccine made by an institute under Sinopharm CNBG in Beijing. The vaccine has proven to be effective and safe. pic.twitter.com/k9VXBTbeCh
— Global Times (@globaltimesnews) June 28, 2020
“People who received two doses of the vaccine at an interval of 28 days, saw their neutralizing antibody-positive conversion rate reach 100 percent,” experts maintained.
On April 12, the vaccine obtained the world’s first clinical trial approval, and phase one and two clinical trials were then launched in Wuzhi county of Henan province. The vaccine will prove to be a breakthrough to contain the spread of COVID-19.
The experts focused on the changes in cellular immunity after vaccination and explored vaccination procedures, immunization dosage, safety, immunogenicity and changes in antibody levels in vivo. Up to now, all the 1,120 subjects that took part in Phase I/II clinical studies have completed two injections.
The clinical trial results showed that the vaccination was safe without any serious adverse reaction, and after different procedures and different doses of vaccination were adopted, participants in the vaccine group all produced high titers of antibodies.
For those aged 18-59 who received two medium-dose injections through the 14-day and 21-day interval procedures, they had a neutralizing antibody-positive conversion rate of 97.6%.
For those who received two medium-dose injections at an interval of 28 days, the neutralizing antibody-positive conversion rate reached 100%.
The CNBG is now actively developing overseas cooperation in Phase III clinical research and has confirmed cooperative intentions with companies and institutions in various countries.
ADVERTISEMENT
